Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 22192-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#22192-1-AP, RRID:AB_11232227
- Product name
- CHRNB4 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated CHRNB4 antibody (Cat. #22192-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse and has been validated for the following applications: FC, WB,ELISA.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references An Integrated Genomic Strategy to Identify CHRNB4 as a Diagnostic/Prognostic Biomarker for Targeted Therapy in Head and Neck Cancer.
Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA.
Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth.
Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets.
Chuang YH, Lee CH, Lin CY, Liu CL, Huang SH, Lee JY, Chiu YY, Lee JC, Yang JM
Cancers 2020 May 22;12(5)
Cancers 2020 May 22;12(5)
Differential Expression of Nicotine Acetylcholine Receptors Associates with Human Breast Cancer and Mediates Antitumor Activity of αO-Conotoxin GeXIVA.
Sun Z, Zhangsun M, Dong S, Liu Y, Qian J, Zhangsun D, Luo S
Marine drugs 2020 Jan 17;18(1)
Marine drugs 2020 Jan 17;18(1)
Identification of nicotinic acetylcholine receptor subunits in different lung cancer cell lines and the inhibitory effect of alpha-conotoxin TxID on lung cancer cell growth.
Qian J, Liu YQ, Sun ZH, Zhangsun DT, Luo SL
European journal of pharmacology 2019 Dec 15;865:172674
European journal of pharmacology 2019 Dec 15;865:172674
Cervical Cancer Correlates with the Differential Expression of Nicotinic Acetylcholine Receptors and Reveals Therapeutic Targets.
Liu Y, Qian J, Sun Z, Zhangsun D, Luo S
Marine drugs 2019 Apr 28;17(5)
Marine drugs 2019 Apr 28;17(5)
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The CHRNB4 antibody from Proteintech is a rabbit polyclonal antibody to a fusion protein of human CHRNB4. This antibody recognizes human, mouse antigen. The CHRNB4 antibody has been validated for the following applications: ELISA, WB analysis.